[Clinical reevaluation of ofloxacin (OFLX) in urinary tract infections].

Abstract

The clinical efficacy of the new quinolone antibacterial agent ofloxacin (OFLX) on urinary tract infections (UTI) was reevaluated. A 400-600 mg dose per day of OFLX was administered to 85 adult patients with various kinds of UTI. OFLX was effective clinically in 92.6% of the patients with acute UTI without urinary tract complications. In 81.8% of the patients with chronic complicated UTI because of organic or functional urinary tract disorders, OFLX was effective. This drug also has a marked bacteriological efficacy. No side effects or abnormal laboratory findings were seen in any of the patients administered OFLX.

• Authors: T Akiyama, T Matsuura, T Kurita
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 34 Issue 1 Pg. 201-4 (Jan 1988) ISSN: 0018-1994 [Print] Japan
• PMID: 3163875 (Publication Type: English Abstract, Journal Article)

Chemical References

• Oxazines
• Ofloxacin

Topics

• Adult
• Aged
• Aged, 80 and over
• Drug Evaluation
• Humans
• Middle Aged
• Ofloxacin
• Oxazines (therapeutic use)
• Urinary Tract Infections (drug therapy)